Indirect mechanisms of genotoxicity.
Indirect mechanisms of genotoxicity correspond to interactions of mutagens with non-DNA targets, and are expected to show threshold concentration-effect response curves. If these thresholds can be proven experimentally they may provide a third alternative for risk assessment, besides the No Effect Level/Safety Factor approach and the low dose linear extrapolation method. We contributed significantly to the in vitro assessment of thresholds in human lymphocytes exposed to the spindle inhibitors nocodazole and carbendazim showing dose dependency and existence of lower thresholds for induction of non-disjunction as compared to chromosome loss. Micronuclei correlated with p53-independent or p53-dependent apoptosis and elimination of aneuploid cells. Extrapolation from in vitro threshold values to the in vivo situation remains unsolved. Comparing the in vitro threshold values for griseofulvin in human and rat lymphocytes with in vivo NOAEL/LOAEL in bone marrow/gut/erythrocytes suggests that the in vitro human system is the most sensitive. The threshold for induction of non-disjunction in in vitro maturing, nocodazole-exposed mouse oocytes was in the same low range. Regulators (UK Committee on Mutagenicity, http://www.doh.gov.uk/com/com.htm) considered the importance of thresholds for indirect mechanisms of genotoxicity. Acceptance of a non-linear extrapolation for mutagens requires mechanistic studies identifying the mutagen/target interactions. Moreover appropriate risk evaluation will require additional studies on individual susceptibility for indirect mutagenic effects and on interactions of aneugens in complex mixtures.
Kirsch-Volders
Micheline
M
Laboratory for Cell Genetics, Vrije Universiteit Brussel, Pleinlaan 2, B-1050, Brussels, Belgium. mkirschv@vub.ac.be
Vanhauwaert
Annelies
A
Eichenlaub-Ritter
Ursula
U
Decordier
Ilse
I
D000818:Animals; D004305:Dose-Response Relationship, Drug; D006118:Griseofulvin / Q000008:administration & dosage / Q000633:toxicity*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects; D009152:Mutagenicity Tests / Q000379:methods*; D009153:Mutagens / Q000008:administration & dosage / Q000633:toxicity*; D018570:Risk Assessment; D020711:Threshold Limit Values
D009153:Mutagens; D006118:Griseofulvin